Matrix metalloproteinases

British Journal of Surgery

Volumn 84, Issue 2, 1997, Pages 160-166

  Parsons, S L ^a   Watson, S A ^a   Brown, P D ^b   Collins, H M ^a   Steele, R J C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b British Biotech Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; GELATINASE; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; CLASSIFICATION; DIGESTIVE SYSTEM CANCER; ENZYME ACTIVITY; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW; WOUND HEALING;

CLINICAL TRIALS; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; GASTROINTESTINAL NEOPLASMS; HUMANS; METALLOENDOPEPTIDASES; NEOPLASM INVASIVENESS; WOUND HEALING;

EID: 0031026874     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840206     Document Type: Review

References (99)

1. Wolf C, Chenard MP, Durand de Grossouvre P, Bellocq JP, Chambon P, Basset P. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing. J Invest Dermatol 1992; 99: 870-2.
2. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64-8.
3. Jeffrey J. Collagen and collagenase: pregnancy and parturition. Semin Perinatol 1991; 15: 118-26.
4. Delaisse J-M, Vacs G. Mechanism of mineral solubilisation and matrix degradation in osteoclastic bone resorption. In Rifkin BR, Gay CV, eds. Biology and Physiology of the Osteoclast. Raton, Florida: CRC Press, 1992; 290-314.
5. Talhouk R, Bissel M, Werb Z. Co-ordinated expression of extracellular matrix degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992; 118: 1271-82.
6. Harris E. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-89.
7. Page RC. The role of inflammatory mediators in the pathogenesis of periodontal disease. J Periodont Res 1991; 26: 230-42.
8. Matrisian L. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121-5.
9. Bassett P, Bellocq JP, Wolf C et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature 1990; 348: 699-704.
10. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994; 370: 61-5.
11. Kleiner D. Stetler-Stevenson W. Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 1994; 218: 325-9.
12. Brown PD, Bloxidge RE, Anderson E, Howell A. Expression of activated gelatinase in human invasive breast carcinoma. Clin Exp Metastasis 1993; 11: 183-9.
13. Brown P, Levy A, Margulies I, Liotta L, StetlerStevenson W. Independent expression and cellular processing of M(r) 72 000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res 1990; 50: 6184-91.
14. David L, Nesland J, Holm R et al. Expression of laminin, collagen IV. fibronectin, and type IV collagenase in gastric carcinoma. Cancer 1994; 73: 518-27.
15. Hewitt RE, Leach IH, Powe DG, Clarke IM, Cawston TE, Turner DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991; 49: 666-72.
16. D'Errico A, Garbisa S, Liotta L, Astronovo V, StetlerStevenson W, Grigioni W. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric and breast carcinoma progression. Mod Pathol 1991; 4: 239-46.
17. Daidone M, Silvestrini R, D'Errico A et al. Laminin receptors, collagenase IV and prognosis in node negative breast cancers. Int J Cancer 1991; 48: 529-32.
18. Porte H, Chastre E, Prevot S et al. Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. Int J Cancer 1995; 64: 70-5.
19. Rodgers WH, Osteen KG, Matrisian LM, Navre M, Giudice LC, Gorstein F. Expression and localization of matrilysin, a matrix metalloproteinase, in human endometrium during the reproductive cycle. Am J Obstet Gynecol 1993; 168: 253-60.
20. Matrisian LM. Matrix metalloproteinase gene expression. Ann N Y Acad Sci 1993; 732: 42-50.
21. Hibbs M, Hoidal J, Kang A. Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages. J Clin Invest 1987; 80: 1644-50.
22. Hoyhtya M, Fridman R, Komarek D et al. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int J Cancer 1994; 56: 500-5.
23. Pyke C, Ralfkiaer E, Tryggvason K, Dano K. Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am J Pathol; 1993; 142: 359-64.
24. Zeng ZS, Guillem JG. Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br J Cancer 1995; 72: 575-82.
25. Satoh K, Ohtani H, Shimosegawa T, Koizumi M, Sawai T, Toyota T. Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas. Gastroenterology 1994; 107: 1488-95.
26. Newell KJ, Witty JP, Rodgers WH, Matrisian LM. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog 1994; 10: 199-206.
27. Gallegos NC, Smales C, Savage FJ, Hembry RM, Boulos PB. The distribution of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal cancer. Surg Oncol 1995; 4: 21-9.
28. Basset P, Wolf C, Chambon P. Expression of the stromelysin-3 gene in fibroblastic cells of invasive carcinomas of the breast and other human tissues: a review. Breast Cancer Res Treat 1993; 24: 185-93.
29. Yamamoto H, Itoh F, Hinoda Y et al. Expression of matrilysin mRNA in colorectal adenomas and its induction by truncated fibronectin. Biochem Biophys Res Commun 1994; 201: 657-64.
30. Wasylyk C, Gutman A, Nicholson R, Wasylyk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. EMBO J 1991; 10: 1127-34.
31. Okada Y, Morodomi T, Enghild J et al. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem 1990; 194: 721-30.
32. Okada Y, Gonoji Y, Naka K et al. Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT1080 human fibrosarcoma cells. J Biol Chem 1992; 267: 21 712-19.
33. Okada Y, Tsuchiya H, Shimizu H et al. Induction and stimulation of 92-kDa gelatinase/type IV collagenase production in osteosarcoma and fibrosarcoma cell lines by tumour necrosis factor alpha. Biochem Biophys Res Commun 1990; 171: 610-17.
34. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990; 29: 10261-70.
35. Sang QX, Birkedal-Hansen H, Van Wart HE. Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta 1995; 1251: 99-108.
36. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995; 55: 2548-55.
37. Crabbe T, Smith B, O'Connell JP, Docherty A. Human progelatinase A can be activated by matrilysin. FEBS Lett 1994; 345: 14-16.
38. Ito A, Nakajima S, Sasaguri Y, Nagase H, Mori Y. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995; 71: 1039-45.
39. Murphy G, Willenbrock F. Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol 1995; 248: 496-510.
40. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331-8.
41. Overall CM. Regulation of tissue inhibitor of matrix metalloproteinase expression. Ann N Y Acad Sci 1994; 732: 51-64.
42. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989; 109: 877-89.
43. Grigioni WF, D'Errico A, Fortunate C et al. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. Mod Pathol 1994; 7: 220-5.
44. Overall CM, Wrana JL, Sodek J. Independent regulation of collagenase, 72-kDa progelatinase, and metalloendoproteinase inhibitor expression in human fibroblasts by transforming growth factor-beta. J Biol Chem 1989; 264: 1860-9.
45. Bramhall S, Lemoine N, Stamp G et al. Enhanced expression of matrix metalloproteinases is often unopposed by their inhibitors (tissue inhibitors of metalloproteinases) in pancreatic cancer. Br J Surg 1995; 82: 707-8 (Abstract).
46. Overall C, Wrana J, Sodek J. Transforming growth factor-beta regulation of collagenase, 72 kDa progelatinase, TIMP and PAI-1 expression in rat bone cell populations and human fibroblasts. Connect Tissue Res 1989; 20: 289-94.
47. Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol 1990; 1: 99-106.
48. Ballin M, Gomez DE, Sinha CC, Thorgeirsson UP. Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun 1988; 154: 832-8.
49. Bernhard E, Muschel R, Hughes E. Mr 92000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells. Cancer Res 1990; 50: 3872-7.
50. Reich R, Thompson E, Iwamoto Y et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48: 3307-12.
51. Nakajima M, Welch DR, Wynn DM, Tsuruo T, Nicolson GL. Serum and plasma M(r) 92 000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma. Cancer Res 1993; 53: 5802-7.
52. Schwartz GK, Wang H, Lampen N, Altorki N, Kelsen D, Albino AP. Defining the invasive phenotype of proximal gastric cancer cells. Cancer 1994; 73: 22-7.
53. Koshikawa N, Yasumitsu H, Umeda M, Miyazaki K. Multiple secretion of matrix serine proteinases by human gastric carcinoma cell lines. Cancer Res 1992; 52: 5046-53.
54. Yamagata S, Yoshii Y, Suh JG, Tanaka R, Shimizu S. Occurrence of an active form of gelatinase in human gastric and colorectal carcinoma tissues. Cancer Lett 1991; 59: 51-5.
55. Nomura H, Sato H, Seiki M, Mai M, Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res 1995; 55: 3263-6.
56. McDonnell S, Navre M, Coffey RJ Jr, Matrisian LM. Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 1991; 4: 527-33.
57. Keeling N, Mukai M, Jonas S, Wastell C. Increased expression of matrilysin (MMP 7) in gastric cancer and lymph node metastases. Br J Surg 1995; 82: 690 (Abstract).
58. Della Porta P, Ryan NM, Collins KJ. Expression of gelatinolytic activity by oesophageal and colon carcinoma cell lines. Biochem Soc Trans 1995; 23: 391S.
59. Yoshimoto M, Itoh F, Yamamoto H, Hinoda Y, Imai K, Yachi A. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer 1993; 54: 614-18.
60. Watson SA, Morris TM, Parsons SL, Steele RJC, Brown PB. Therapeutic effect of the matrix metalloproteinase inhibitor Batimastat in a human colorectal cancer ascites model. Br J Cancer 1996; 74: 1354-8.
61. Ambiru S, Miyasaki M, Nakagawa K, Nakajima N. Increased serum type IV collagen 7-S levels in patients with hepatic metastasis. Am J Gastroenterol 1995; 90: 783-7.
62. Parsons S, Watson S, Collins H, Clarke P, Steele R. Colorectal cancers overexpress gelatinases (matrix metalloproteinases-2 and -9). Gastroenterology 1996; 110: A574 (Abstract).
63. Mori M, Barnard GF, Mimori K, Ueo H, Akiyoshi T, Sugimachi K. Overexpression of matrix metalloproteinase-7 mRNA in human colon carcinomas. Cancer 1995; 75 (Suppl 6): 1516-19.
64. Murray G, Duncan M, O'Neil P, Melvin W, Fothergill J. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nature Medicine 1996; 2: 461-2.
65. Taniguchi S, Iwamura T, Katsuki T. Correlation between spontaneous metastatic potential and type 1 collagenolytic activity in a human pancreatic cell line (SUIT-2) and sublines. Clin Exp Metastasis 1992; 10: 259.
66. Zucker S, Lysik R, Wieman J, Wilkie D, Lane B. Diversity of human pancreatic cancer cell proteinases: role of cell membrane metalloproteinases in collagenolysis and cytolysis. Cancer Res 1985; 45: 6168.
67. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62: 407-13.
68. Sipos E, Tamargo R, Weingart J, Brem H. Inhibition of tumour angiogenesis. Ann N Y Acad Sci 1994; 732: 263-72.
69. Moses M, Sudhalter J, Langer R. Identification of an inhibitor of neovascularisation from cartilage. Science 1990; 248: 1408-10.
70. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA. Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2-(hydroxamidocarbonymethyl)-4-methylpentanoyl)]-1-tryptophan methylamide. Cancer Res 1994; 54: 4715-18.
71. Taraboletti G, Garofalo A, Belotti D. Inhibition of angiogenesis and murine hemangioma growth by Batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995; 87: 293-8.
72. Potgens A, Lubsen N, van Altena M et al. Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice. Am J Pathol 1995; 146: 197-209.
73. Kim K, Li B, Winer J et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vitro. Nature 1993; 362: 841-4.
74. Unemori E, Ferrara N, Bauer E, Amento E. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557-62.
75. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol 1995; 105: 170-6.
76. 2, and proliferation in human fibroblasts. Exp Cell Res 1994; 210: 166-71.
77. Sato T, Makela M, Kylmaniemi M, Autio-Harmainen H, Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994; 70: 176-82.
78. Baragwanath P, Hopkinson I, Evans D, Jasani B, Harding K, Mansel R. Chronic human wounds are associated with elevated tissue levels of MMP-9 (92 kDa gelatinase). Br J Surg 1996; 83: 684-5 (Abstract).
79. Chowcat N, Savage F, Lewis M, Boulos P. Direct measurement of collagenase in colonic anastomosis. Br J Surg 1990; 77: 1284-7.
80. Cunliffe W, Sugarbaker P. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 1989; 76: 1082-90.
81. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WG. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991; 83: 775-9.
82. Schultz R, Silberman S, Persky B et al. Inhibition of human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonisation by murine B16-F10 melanoma cells. Cancer Res 1988; 48: 5539-45.
83. Tsuchiya Y, Sato H, Endo Y et al. Tissue inhibitor of metalloproteinase-1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 1993; 53: 1397-402.
84. Alvarez OA, Carmichael DF, DeClerck YA. Inhibition of collagenolytic activity and metastasis of tumour cells by a recombinant human tissue inhibitor of metalloproteinases. J Natl Cancer Inst 1990; 82: 589-95.
85. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299-304.
86. DeClerck Y, Perez N, Shimada H et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-8.
87. Hoyhtya M, Hujanen E, Turpeenniemi-Hujanen T et al. Modulation of type IV collagenase activity and invasive behavior of metastatic human melanoma (A2058) cells in vitro by monoclonal antibodies to type IV collagenase. Int J Cancer 1990; 46: 282-6.
88. French D, Ramos-Desimone N, Rozinski K, Nuovo G. Matrix metalloproteinase-9 in tumour cell invasion. Ann N Y Acad Sci 1994; 732: 325-34.
89. Davies B, Brown P, East N, Crimmin M, Balkwill F. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993; 53: 2087-91.
90. Watson SA, Morris TM, Robinson G, Crimmin MJ, Brown PD, Hardcastle JD. Inhibition of organ invasion by the matrix metalloproteinase inhibitor Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33.
91. Chirivi RG, Garofalo A, Crimmin MJ et al. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Int J Cancer 1994; 58: 460-4.
92. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994; 54: 4726-8.
93. Drummond A, Beckett P, Bone E et al. BB-2516: an orally bioavailable matrix metalloproteinase inhibitor with efficacy in animal cancer models. Proc Am Assoc Cancer Res 1995; 36: 100 (Abstract).
94. Galardy RE, Cassabonne ME, Giese C. Low molecular weight inhibitors in corneal ulceration. Ann N Y Acad Sci 1994; 732: 315-23.
95. Macaulay V, O'Byrne K, Saunders M et al. Phase I study of the matrix metalloproteinase inhibitor Batimastat (BB-94) in patients with pleural effusions. Br J Cancer 1995; 71: 11 (Abstract).
96. Parsons S, Watson S, Amar S, Steele R. Phase I/II trial of a matrix metalloproteinase inhibitor in patients with malignant ascites. Gastroenterology 1996; 110: A575 (Abstract).
97. Parsons SL, Watson SA, Griffin NR, Tierney GM, Steele RJC. An open phase 1/11 study of the oral matrix metalloproteinase inhibitor, Marimastat, in patients with inoperable gastric cancer. Ann Oncol 1996; 7(Suppl 5): 47.
98. Lee W, Aiken S, Kulkarni G et al. Collagenase activity in recurrent periodontitis: relationship to disease progression and doxycycline therapy. J Periodont Res 1991; 26: 479-85.
99. Vincenti MP, Clark IM, Brinckerhoff CE. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum 1994; 37: 1115-26.